Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an 18F-AV-45 study.

Background Positron emission tomography (PET) with the radiotracer florbetapir (18F-AV-45) allows the pathophysiology of Alzheimer's disease (AD) to be tracked in vivo. The semi-quantification of amyloid-beta (Aβ) has been extensively evaluated with the standardized uptake value ratio (SUVR) but is susceptible to disturbance from the candidate reference region and the partial volume effect (PVE). In the present study, we applied the parametric estimation of reference signal intensity (PERSI) method to 18F-AV-45 PET images for intensity normalization. Methods We enrolled 479 people with 18F-AV-45 images from the Alzheimer's Disease Neuroimaging Initiative database: 261 healthy controls (HCs), 102 patients with mild cognitive impairment (MCI), and 116 AD patients. We used white matter post-processed by PERSI (PERSI-WM) as the reference region and compared our proposed method with the traditional method for semi-quantification. SUVRs were calculated for eight regions of interest: the frontal lobe, the parietal lobe, the temporal lobe, the occipital lobe, the anterior cingulate cortex, the posterior cingulate cortex, the precuneus, and the global cortex. The SUVRs derived from PERSI-WM and other reference regions were evaluated by effect size and receiver-operator characteristic curve analyses. Results The SUVRs derived from PERSI-WM showed significantly higher trace retention in the frontal, parietal, temporal, and occipital lobes, as well as in the anterior cingulate, posterior cingulate, precuneus, and global cortex in the AD Aβ-positive (+) group (mean: +43.3%±5.4%, P<0.01) and MCI Aβ+ group (mean: +29.6%±5.3%, P<0.01). For the global cortex, PERSI-WM had the greatest Cohen's d effect size compared with the HC Aβ-negative (-) group (AD Aβ+ and MCI Aβ+: 3.02, AD Aβ+: 3.56, MCI Aβ+: 2.34), and the highest area under the curve (AUC) between the HC Aβ- and AD Aβ+ groups (AUC: 0.983, 95% confidence interval: 0.978-0.998). Conclusions PERSI-WM could mitigate the influence of PVE and improve the semi-quantification of 18F-AV-45 images; therefore, it could be used for large-scale clinical application in the nuclear medicine domain.

[1]  Shengwen Guo,et al.  Identifying subtypes of mild cognitive impairment from healthy aging based on multiple cortical features combined with volumetric measurements of the hippocampal subfields. , 2020, Quantitative imaging in medicine and surgery.

[2]  Iraj Nabipour,et al.  An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care. , 2019, Quantitative imaging in medicine and surgery.

[3]  Junjie Yao,et al.  Imaging the aged brain: pertinence and methods. , 2019, Quantitative imaging in medicine and surgery.

[4]  W. Jagust Imaging the evolution and pathophysiology of Alzheimer disease , 2018, Nature Reviews Neuroscience.

[5]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[6]  M. Mintun,et al.  Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity , 2017, The Journal of Nuclear Medicine.

[7]  Steven Staelens,et al.  Validation of the Semiquantitative Static SUVR Method for 18F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function , 2017, The Journal of Nuclear Medicine.

[8]  Ralph Buchert,et al.  PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET – Application to amyloid imaging with AV45-PET , 2017, NeuroImage.

[9]  Hanna Cho,et al.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.

[10]  John Seibyl,et al.  Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans , 2016, The Journal of Nuclear Medicine.

[11]  S. Shokouhi,et al.  Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment , 2016, Alzheimer's Research & Therapy.

[12]  Oscar L Lopez,et al.  Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET , 2015, The Journal of Nuclear Medicine.

[13]  Daniel Bandy,et al.  Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region , 2015, The Journal of Nuclear Medicine.

[14]  William J. Jagust,et al.  Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.

[15]  John Seibyl,et al.  Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.

[16]  Keith A. Johnson,et al.  Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.

[17]  Rik Ossenkoppele,et al.  Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.

[18]  Yong He,et al.  BrainNet Viewer: A Network Visualization Tool for Human Brain Connectomics , 2013, PloS one.

[19]  Masanori Ichise,et al.  PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.

[20]  T. Yen,et al.  Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[22]  Keith A. Johnson,et al.  Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease , 2013, Neurobiology of Aging.

[23]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[24]  D. Holtzman,et al.  Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. , 2012, Current opinion in neurology.

[25]  I. Buvat,et al.  A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology , 2012, Physics in medicine and biology.

[26]  Keith A. Johnson,et al.  Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline , 2012, Neurology.

[27]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[29]  Tyler E. Benedum,et al.  Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain , 2009, Journal of Nuclear Medicine.

[30]  R. Vandenberghe,et al.  Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging , 2009, Journal of Nuclear Medicine.

[31]  Sakari Savolainen,et al.  Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. , 2008, Archives of neurology.

[32]  Sung-Cheng Huang,et al.  Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[34]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[35]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[36]  J Mazziotta,et al.  A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[37]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  Jerry L Prince,et al.  Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: MRI-Based Correction for Partial Volume Effects , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  Quantitative Imaging in Medicine and Surgery , 2013 .

[40]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.